Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Other hematologic neoplasm 2Myeloid 2Dermatologic 2Genitourinary 1Classical hematology 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Docetaxel 77Radiotherapy 73Prednisone 65Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 41Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 30Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Triptorelin Pamoate 23Sunitinib 23Nivolumab 23Radiation 22apalutamide 21Doxorubicin 20darolutamide 18Gonadotropin-Releasing Hormone 18cabozantinib 16abiraterone 16Specimen Handling 16Radiosurgery 16Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Colony-Stimulating Factors × Genitourinary × Clear all
NCT01265901 2017-10-12

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Immatics Biotechnologies GmbH

Phase 3 Completed
339 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡